Valuation: Bionik Laboratories Corp.

Market Cap 12 10.54 9.71 9.08 17.03 1.13K 17.34 116.52 45.13 558.17 45.06 44.08 1.94K P/E 2022
-0.21x
P/E 2023 -0.56x
Enterprise Value 1.98M 1.74M 1.61M 1.5M 2.82M 187M 2.87M 19.27M 7.47M 92.33M 7.45M 7.29M 321M EV / Sales 2022
0.17x
EV / Sales 2023 2.65x
Free-Float
100%
Yield 2022 *
-
Yield 2023 -
1 month 0
Extreme 0.0001
0
Current year 0
Extreme 0.0001
0
1 year 0
Extreme 0
0
3 years 0
Extreme 0
0.64
5 years 0
Extreme 0
2.9
10 years 0
Extreme 0
222.02
Manager TitleAgeSince
Chief Executive Officer 46 2021-07-13
Director TitleAgeSince
Director/Board Member 35 2019-03-17
Director/Board Member 70 2017-08-31
Director/Board Member 46 2022-10-12
Date Insider Type Main position Quantity % Market Cap.
23-06-12Conversion

Chairman

186,112 1.4416%
23-06-12Conversion

Director

3,102,878 24.0337%
23-06-08Buy

Director

180,555 1.3985%
Change 5-day change 1-year change 3-year change Capi.($)
+9,900.00%-.--%-.--%-99.98% 1.26K
+0.93%+9.93%+23.77%-2.29% 188B
+1.97%+1.01%-23.81%+25.18% 142B
+1.30%+9.55%-3.11%-17.94% 137B
+1.37%+0.90%-57.23%-16.39% 65.7B
+1.04%+5.04%+16.93%+0.80% 51.66B
-0.55%+0.03%-26.90%-32.25% 43.7B
+0.76%+7.93%+14.32%+15.33% 38.27B
-0.56%+4.87%+5.86%+44.64% 37.01B
+1.48%+8.15%-12.39%-15.70% 29.54B
Average +990.76%+2.68%-6.26%-9.86% 73.21B
Weighted average by Cap. +1.07%+3.25%-4.08%+0.01%

Financials

2022 2023
Net sales 1.27M 1.12M 1.03M 964K 1.81M 120M 1.84M 12.37M 4.79M 59.25M 4.78M 4.68M 206M 1.81M 1.59M 1.46M 1.37M 2.56M 170M 2.61M 17.53M 6.79M 83.97M 6.78M 6.63M 292M
Net income -10.41M -9.14M -8.42M -7.88M -14.77M -982M -15.04M -101M -39.15M -484M -39.09M -38.23M -1.68B -4.95M -4.34M -4M -3.74M -7.02M -467M -7.15M -48.03M -18.6M -230M -18.57M -18.17M -800M
Net Debt -1.99M -1.75M -1.61M -1.51M -2.83M -188M -2.88M -19.34M -7.49M -92.63M -7.48M -7.31M -322M 1.98M 1.74M 1.61M 1.5M 2.82M 187M 2.87M 19.27M 7.47M 92.33M 7.45M 7.29M 321M
Logo Bionik Laboratories Corp.
Bionik Laboratories Corp. is a healthcare company focused on supplying solutions to those with movement impairments. Its product portfolio includes three InMotion Robots for rehabilitation following stroke and other neurological conditions and four products in varying stages of development. The InMotion robots offer patient-adaptive therapy, intended to restore upper-extremity motor control for a range of neurological conditions and recovery stages, including early recovery from acute stroke. InMotion Robots also provide objective evaluation assessments intended to measure and report the patient’s level of motor impairment and progress during therapy. Its solutions include InMotion Therapy, InMotion ARM, InMotion ARM/HAND, InMotion EVAL, InMotion Connect, InMotion for Physical Therapy, and InMotion for Occupational Therapy. InMotion Robotics provides the occupational therapist with a range of useful protocols designed to reduce many types of upper extremity neurological impairments.
Employees
12
  1. Stock Market
  2. Stocks
  3. BNKL Stock